1 Min Read
Aug 25 (Reuters) - Mayne Pharma Group Ltd:
* FY revenue from ordinary activities up 114% to $572.6 million
* FY profit attributable to equity holders of parent $88.6 million versus $37.4 million Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.